The adjuvant treatment of sepsis remains a major therapeutic challenge. Blood purification is theoretically appealing if the humoral theory of sepsis is accepted as the basis for intervention. In this setting, blood purification would provide a broad-based restoration of humoral homeostasis thereby avoiding both excessive inflammation and counterinflammation. Several techniques of blood purification have been tried or are under active investigation. One of these is the so-called coupled plasma filtration adsorption (CPFA). CPFA is a novel extracorporeal blood purification therapy aimed at nonselectively reducing the circulating levels and activities of both pro-and anti-inflammatory mediators during sepsis and multiorgan failure. In vitro studies have shown CPFA to be effective in binding a broad range of such mediators proving its technical efficacy. Subsequent animal models have shown a beneficial effect on survival in endotoxemia. These studies have provided the necessary technical developments and biologic rationale for initial human studies. Two phase I/IIa clinical studies have now been performed. Both studies have shown that CPFA improves blood pressure and restores immune function in patients with severe sepsis and multiorgan dysfunction. In this article, we will discuss some of the basic principles involved in sorbent technology, and how these may contribute to treatment efficacy, review animal experiments with CPFA and finally discuss the results of recent human studies and their implications.
We still lack a good definition of sepsis. There have been many attempts to better define clinical symptoms, categories and scoring systems; however, as time passes, the definitions always seem to grow more complex in spectrum.
Early attempts at treatment met with failure due to oversimplistic approaches to treatment. It was thought that, if an infectious agent was responsible for sepsis, early intervention by neutralizing the infectious agent or a component of the early phases of the inflammatory cascade would result in prevention of the secondary symptoms. Often, approaches using animal models that utilized targets towards specific mediators or endotoxin had some success due to the controlled nature of the experiment. These 'magic bullets' often stirred excitement within the medical community, only to be met with great disappointment after their failure during human clinical trials.
Other attempts to define sepsis looked at a more systemic approach to the pathology. Pinsky [2] suggested that sepsis was a 'malignant form of intravascular inflammation'. Others have suggested that it may be more of 'a type of disseminated local inflammation in which the actual process occurs at the tissue level' [3] . In this case, the increase in plasma cytokines is thought to originate from 'spillage' from the local sites into the circulation with consequent disseminated inflammation. What seems to be the accepted operating paradigm at this time is that sepsis is an exaggerated immune response to infection that includes the production and release of a wide array of both pro-and anti-inflammatory molecules.
Coupled plasma filtration adsorption (CPFA) is an extracorporeal therapy that utilizes a plasma filter to separate plasma from the blood and then allows passage of the separated plasma through a sorbent cartridge for the nonspecific removal of various mediators [4] [5] [6] [7] [8] . After purification, the plasma is returned to the blood. The blood can then pass through a hemodialyzer/hemofilter for additional blood purification by conventional hemodialysis, hemofiltration or hemodiafiltration in patients who have acute renal failure (ARF) ( fig. 1 ). The treatment goal of CPFA is to target the excess of circulating mediators (both pro-and anti-inflammatory molecules) in order to restore normal immune function. Figure 2 shows a diagrammatic scheme of inflammatory cell activation and hyporesponsiveness and how these may relate to the amplified response seen in septic patients.
The development of CPFA was a complex process that underwent numerous evolutionary changes to find a suitable resin with good adsorption for a wide variety of mediators and at the same time suitable for extracorporeal therapy. Historically, the use of resins or sorbents appeared an attractive concept to achieve blood purification. Hemoperfusion was used in animals as early as 1948 to test the removal of urea with an Amberlite ion exchange resin [9] . This was followed by the use of a lactated anion exchange resin by Schreiner in 1958 for a patient with pentobarbital poisoning and various other attempts in the mid 1960s [10] [11] [12] [13] . These early trials were associated with severe side effects which included hemolysis, electrolyte disturbances, pyrogenic reactions and thrombocytopenia. Attempts to increase the biocompatibility of such resins by external coating of the matrix often led to compromises in adsorption efficacy.
Today, there is an renewed interest in the use of sorbent techniques to complement other types of extracorporeal blood purification therapies. There is a wide range of commercial adsorption therapies ranging from specific adsorption therapies such as a polymyxin B endotoxin adsorbing resin to more generalized or combination systems for artificial liver support devices [14] [15] [16] [17] [18] .
How Do Sorbents Work?
The resin used in the CPFA sorbent cartridge was chosen based on its adsorption capacity for inflammatory mediators, low levels of extractable toxins/metals and good pressure-flow performance. This section will describe in greater detail some of the basic characteristics of the sorbent cartridge and the mechanisms responsible for the inflammatory mediator removal.
The resin used in CPFA sorbent cartridge is a synthetic cross-linked styrenic divinylbenzene resin. This type of resin is used in diverse processes ranging from laboratory chromatography to industrial purification of foods, beverages and pharmaceuticals. The resin is well suited for extracorporeal applications because of its high homogeneity, good pressure-flow performance, and excellent mechanical and chemical stability. In addition to its mechanical properties, the choice of this particular resin was based on several different factors related to its capacity to adsorb a wide variety of inflammatory mediators Separate and retain pro-and anti-inflammatory molecules that are produced in excess of normal physiological levels
The primary treatment goal is to retain excess molecules within the resin; a secondary goal is the eventual restitution of physiological molecules and the avoidance of large amounts of exogenous reinfusion fluid
Works with well-defined mobile phase that can be modified by the user (polarity, mixed solvents, pH, salt concentration)
In this case, the mobile phase is actually the patient's plasma
This creates a unique milieu that varies from individual to individual and that can change over the treatment period In this regard, it may be useful to compare the processes that occur during the adsorption of mediators with CPFA with similar processes that occur in traditional chromatography (table 1) . Chromatography is commonly used to separate molecules from a complex mixture. There are many factors that can influence this process and many of the important factors are summarized in table 2. Traditional column chromatography has two important phases: the mobile phase (the fluid or solvent that moves through the column) and the stationary phase (the 'resin' or matrix). The active sites of the stationary phase interact with the functional groups of the compound to be separated by noncovalent bonds, nonpolar interactions, van der Waals forces and hydrophobic interactions. The less tightly bound compounds are eluted out by the mobile phase at an earlier time, allowing different classes of compounds or molecules to be separated. The mobile phase can be easily changed by using a combination of different solvents. In the case of CPFA, the patients' plasma is a complex milieu that contains a wide variety of excess mediators, as well as lipids, proteins and other physiologically important molecules. The patients' plasma can be considered the mobile phase and the treatment goal is to maximize the interaction of the mediators with the resin so that they will prefer the resin and be retained in the cartridge. This is not an easy task as the excess inflammatory mediators have a wide range of sizes and different physicochemical properties.
There are several factors that are important in determining the adsorption efficacy of the resin. These include: the type of resin, and the size and the internal pores of the resin bead. Resins vary greatly in their chemical properties. The resin used for CPFA is a reverse phase-type resin that interacts with hydrophobic sites on the molecule. The pore size can be important as pore dimensions limit the size of the molecules that can cross them. An important concept related to the size of the molecule is the Stokes' radius ( fig. 3) . In aqueous solutions, molecules rotate around their center of gravity describing a sphere that corresponds to their effective size. The radius of this 'sphere' governs the access of the molecules to the matrix pores. The capacity of the resin refers to the quantity of a given molecule that is adsorbed by a specific quantity of resin.
In vitro Experiments
The resin for CPFA was initially tested under static conditions to determine the binding capacity for pro-and anti-inflammatory mediators. Individual mediators were first tested by adding a known quantity of the mediator to saline and observing the adsorption to a small quantity of resin in a test tube. The adsorption could then be easily measured by monitoring the concentration in the supernatant. This method allowed a general assessment of adsorption for a wide variety of inflammatory mediators and different sorbents. Some of the various sorbents that were tested included activated carbon, ion exchange resins and several reverse phase resins with varying bead and pore dimensions.
The next step involved adding the inflammatory mediators to healthy control plasma, incubating this with a small amount of resin and then monitoring the supernatant. Not surprisingly, the adsorption can change dramatically when incubated with saline versus plasma. An example of this difference was found for the high binding of · 2 -macroglobulin from plasma. This protein has a high affinity for several cytokines. In some cases, cytokines that had only moderate binding to the resin in saline showed dramatically improved binding after they had been added to plasma. It appeared that this was a consequence of the fact that · 2 -macroglobulin was able to bind to the resin and subsequently the cytokine became bound to the · 2 -macroglobulin. Thus, the resin became an effective remover of cytokines in plasma not through direct cytokine binding but through an intermediary step. A final step for the completion of static measurements included incubating whole blood with endotoxin to produce a wide array of inflammatory mediators, isolating the plasma and then incubating the plasma with the resin in the test tube. All of these different static tests helped choose resins that have a good capacity for the molecules of interest. After several resins had been chosen for their adsorptive capacity, they were then evaluated for safety (leachable toxins or metals), ability to be sterilized and mechanical stability. The optimization of flow and column geometry is a parameter that also greatly influences adsorption efficacy. The linear velocity is a term that describes the relationship between fluid speed (and thus the sample components) and a flow path. It is typically reported as centimeters per hour. Since the linear velocity is related to the square of the column radius, it is directly influenced by sample flux through the column and the column radius.
Linear velocity = flux cm 3 /h area cm 2 Some resins have good adsorption of a particular molecule over a wide range of linear velocities, while others may have a dramatic decrease in adsorption as the linear velocity increases (fig. 4) . This translates into an important point related to plasma adsorption: there is a balance between the volume of plasma being treated and the plasma contact time with the resin. Decreased adsorption efficacy is often observed if plasma flow rate becomes too fast.
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linear structure globular structure Figure 2 shows the influence of linear velocity on sample adsorption for three different resins for an inflammatory mediator. In some cases, the adsorption is quite high at low linear velocities, but the adsorption is greatly diminished at higher linear velocities. It is also possible to see the relationship of column diameter by comparing the diameters of a 'thin' column of 4 cm to a 'wide' column of 8 cm. If there is a flux of 50 ml/min, this will give a linear velocity of 238 cm/h for the 'thin' column and 60 cm/h for the 'wide' column. A small change in column diameter can greatly influence the linear velocity and adsorption, even if the flow rates are similar.
The next series of experiments evaluated resin adsorption under flow conditions in vitro. For these experiments, small cartridges were constructed to enable testing of various resins under the same linear velocity as those expected during plasma filtration (about 20 ml/min). The parameters that were important for these experiments were overall adsorption of mediators in both plasma and saline, good flow performance without any increases in pressure and the absence of fines or small particles that could clog the external safety filter. After careful consideration of the static and dynamic in vitro results, the resin that gave the best overall performance was a 100-Ìm reverse-phase resin with an average pore diameter of 30 nm.
Animal Studies
A rabbit model for endotoxic shock was used to determine whether the use of coupled plasma filtration and adsorption could reduce the 72-hour mortality [19] . Rabbits were subdivided into groups to receive endotoxin plus CPFA, endotoxin with plasma filtration (no resin), CPFA only (no endotoxin) or CPFA plus endotoxin. The rabbits were anesthetized, cannulated and underwent 3 h of treatment. Plasma concentrations of endotoxin, bioactive tumor necrosis factor, resin-adsorbed platelet-activating factor, mean arterial pressure, base excess, and white cell count were assessed and a global severity score was established.
At 72 h, cumulative survival was significantly (p = 0.0041) improved in septic rabbits treated with coupled plasma filtration-adsorption, and cumulative survival of the resin with the lipopolysaccharide group was not significantly different (p 1 0.05) from that of the control groups (plasma filtration or CPFA without any endotoxin).
One of the more surprising results of the study was that survival was not directly correlated with any single parameter (e.g. endotoxin, cytokine, or MAP). Only the global severity score based on severity of several different parameters was inversely correlated with survival. This supports the current trend to a more global treatment of sepsis rather than restricting treatment to specific removal strategies.
Human Clinical Studies
There have been two recent studies using CPFA for septic patients. The first study by Ronco et al. [20] was a pilot cross-over study that compared CPFA with hemodiafiltration by measuring hemodynamics and immune responsiveness in ARF patients with septic shock. In this study, patients were randomly assigned to 10 h of treatment using CPFA followed by 10 h of hemodiafiltration (or vice versa). These authors observed a significant improvement in hemodynamics with the use of CPFA compared with hemodiafiltration. They also observed a significant increase in leukocyte responsiveness after CPFA treatment. For these experiments, they monitored spontaneous and endotoxin-stimulated leukocyte TNF-· production after 10 h of treatment. At the beginning of the treatment, there was a marked leukocyte hyporesponsiveness to endotoxin stimulation (immunosuppression). As the treatment progressed, the responsiveness increased. Further support for the role of CPFA in the restoration of immune responsiveness was observed by incubating preand postresin plasma with monocytes obtained from healthy donors. The preresin plasma at the beginning of treatment had a strong immunosuppressive effect -unless the plasma had first been incubated with monoclonal antibodies to IL-10. In contrast, the postresin plasma (at the beginning of treatment) produced higher quantities of TNF-· after endotoxin challenge, and nearly normal quantities after the 10-hour treatment.
One of the interesting observations of this study was that there were no significant changes in circulating plasma levels of IL-10 or TNF-· even though there was almost complete adsorption of these cytokines by the resin cartridge. This suggests that there may still be other factors that are adsorbed by the cartridge that play a role in immunosuppression. For this reason, the results presented in this study may be particularly relevant as the end point of the study was restoration of immune responsiveness, rather than a net increase or decrease in specific inflammatory mediators.
A second clinical study using CPFA was conducted by Formica et al. [21] . This study examined the effect of repeated applications of CPFA on the hemodynamic response in septic shock patients. One of the unique aspects of this study was that both ARF and non-ARF patients were eligible if they met the enrollment criteria. All patients had a high APACHE II score (24.8 B 5.6) and multiorgan failure. Six of the 10 patients had normal renal function. The authors performed 10 consecutive sessions and observed a net decrease in vasopressor requirement, increased mean arterial pressure and decreased C reactive protein. The patients treated with CPFA had a 70% survival.
Although the sample size was small for both clinical studies, they both showed improved hemodynamics and good treatment tolerance. Further studies are needed to better identify patient groups that may benefit from early intervention in the complex interactions between various immunosuppressive and inflammatory mediators. Today, after a preliminary experimental phase, a specific technology is commercially available to perform CPFA ( fig. 5 ).
Conclusion
Sepsis is a leading cause of ARF in intensive care units; however, the use of extracorporeal blood purification techniques in non-ARF septic patients remains controversial [3, 22, 23] . Current guidelines, for example, state that 'hemofiltration should not be used in patients with sepsis without renal indications unless ongoing studies provide positive results' [24] . The role of plasma exchange remains equally controversial [25, 26] . In contrast, the initial findings with CPFA are consistent and provide provocative observations, which will no doubt encourage clinical investigators to further pursue the path of blood purification. It may be that CPFA will be the first nonrenal blood purification technique to be tested in a phase IIb multicenter randomized controlled trial for the treatment of severe sepsis and multiorgan failure. 
